Sargramostim
Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the proliferation, differentiation, and activation of hematopoietic progenitor cells, particularly granulocytes and monocytes/macrophages. It is used to accelerate myeloid recovery following bone marrow transplantation, treat neutropenia in cancer patients, and mobilize peripheral blood stem cells for collection. Investigational applications include Alzheimer's disease, where GM-CSF may stimulate microglial amyloid clearance.
治疗领域
作用机制
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the proliferation, differentiation, and activation of hematopoietic progenitor cells, particularly granulocytes and monocytes/macrophages. It is used to accelerate myeloid recovery following bone marrow transplantation, treat neutropenia in cancer patients, and mobilize peripheral blood stem cells for collection. Investigational applications include Alzheimer's disease, where GM-CSF may stimulate microglial amyloid clearance.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Sargramostim is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201670. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sargramostim"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sargramostim/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sargramostim/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sargramostim/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sargramostim"></drugfyi-drug>